RxDoctor Payments Data

Rajakrishnan Vijayakrishnan, MD

Advanced Heart Failure and Transplant Cardiology · Milwaukee, WINPI 1871742502

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,494 of the $5,798 with a category attached, or 77.5%. 19 manufacturers reported payments, led by Abbott at 50.7% of the total.

$5,798in general payments, 2019–2025

Across 111 payments — averaging $52.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Abiomed$1K
  • Medtronic$465
  • Amgen$155
  • Cvrx, Inc.$113
  • AstraZeneca$96
  • plus $630 from 13 others

What the payments were for

  • Travel & lodging$1,30422%
  • Food & beverage$4,49478%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$35,045
Medicare patients
86
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan101$111,828
JardianceEmpagliflozin71$69,758
EliquisApixaban53$45,523
FarxigaDapagliflozin Propanediol27$29,884
Bumetanide77$2,497
Isosorbide Dinitrate18$1,614
Metoprolol Succinate95$1,582
Enoxaparin Sodium14$1,471
Warfarin Sodium81$1,430
Pantoprazole Sodium48$963
Torsemide13$737
Rosuvastatin Calcium40$664
Digoxin34$621
Spironolactone98$591
Atorvastatin Calcium42$491

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$80$111,828101 claims
Boehringer IngelheimJardiance$73$69,75871 claims
PfizerEliquis$17$45,52353 claims
AstraZenecaFarxiga$96$29,88427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Wisconsinon file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Milwaukee

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →